Sanofi (NASDAQ:SNY) is one of the Best Low Cost Stocks to Buy According to Analysts. On September 6, Leerink Partners analyst David Risinger maintained a Buy rating on Sanofi (NASDAQ:SNY) without a price target. The analyst acknowledged the challenges faced by the company with Amlitelimab in its Phase 3 trial, as the results did not meet the high benchmark set by Dupixent. However, Risinger noted that Amlitelimab can still achieve its primary and secondary endpoints, showing promise as a second-line treat ...